Erişkin, adolesan ve çocukluk yaş grubunda obeziteye klinik yaklaşım

Rahman YAVUZ, Hacı Ömer TONTUŞ
3.144 1.432

Abstract


Obezitenin artan prevalansı birçok sağlık sorununa neden olmaktadır. Günümüzde diyetle karbonhidrat ve yağ içeriklerinin artmış olması, fiziki aktivitelerden uzaklaşarak, bilgisayar ve televizyon başında daha çok vakit geçirmek, tüm yaş grupları içinde obeziteyi önemli bir toplum sağlığı sorunu haline getirmiştir. Obezite; Diabetes mellitus, hipertansiyon, kalp hastalığı, inme, kanserler, sindirim sistemi hastalıkları gibi hastalıkların artışı ile ilişkilidir.

The clinical approach to the obesity in adult, adolescent and pediatric age groups.

The increasing prevalence of obesity leads to numerous health problems. Today, obesity has become a major public health problem in all age groups because of increased dietary carbohydrate and fat content, moving away from physical activities, spending more time
with computer and television. Obesity is associated with an increase in diseases such as Diabetes mellitus, hypertension, heart disease, stroke, cancer, diseases of the digestive
system.

Keywords


Adolesan; çocuk; erişkin; klinik yaklaşım; obezite; yaş grubu (Adolescent; pediatric; adult; clinical approach; obesity; age group)

Full Text:

69-74


References


Afridi, A., Khan, A., 2004. Prevalence and Etiology of Obesity-An Overview. Pakistan. J. Nutr. 3, 14-25.

Aladağ, N., 2004. Birinci basamakta erişkin obezitesinin yönetimi. Türkiye Klinikleri J. Med. Sci. 24, 508-517.

Barlow, S.E., 2007. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: Summary report. Pediatrics. 120, 164-192.

Caterson, I., Coutinho, W., Finer, N., Van Gaal, L., Maggioni, A., Torp-Pedersen, C., Sharma, A.M., Ge, H., Santoro, D., Shepherd, G., James, P., SCOUT Investigators., 2010. Early response to sibutramine in patients not meeting current label criteria: Preliminary analysis of SCOUT lead-in period. Obesity (Silver Spring). 18, 987-994.

Çelik, G.G., Tahiroğlu, A.Y., Avcı, A., 2011. Çocuk ve ergenlerde atipik antipsikotik ilaçların metabolik ve endokrin yan etkileri. Psikiyatride güncel yaklaşımlar. 3, 232-250.

Christensen, R., Kristensen, P.K., Bartels, E.M., Bliddal, H., Astrup, A., 2007. Efficacy and safety of the weight-loss drug rimonabant: A metaanalysis of randomised trials. Lancet. 370, 1706-1713.

Dişcigil, G., 2007. Günümüzün çocukluk ve adolesan çağı epidemisi: Obezite. Türk Aile Hek. Derg. 11, 92-96.

Erge, S., 2003. Obezitede diyet tedavisini destekleyen davranışsal tedavi. Turkish Journal of Endocrinology and Metabolism. 2, 75-82.

Erkekoğlu, P., Giray, B., Şahin, G., 2007. Çocukluk ve adölesan dönemde kullanılan antiobezitik ilaçların toksikolojik açıdan değerlendirilmesi. Hacettepe Tıp Dergisi. 38, 199-211.

Freemark, M., 2007. Pharmacotherapy of childhood obesity: An evidence-based, conceptual approach. Diabetes Care. 30, 395-402.

Gaylor, A.S., Condren, M.E., 2004. Type 2 diabetes mellitus in the pediatric population. Pharmacotherapy. 24, 871-878

Godoy-Matos, A., Carraro, L., Vieira, A., Oliveira, J., Guedes, E.P., Mattos, L., Rangel, C., Moreira, R.O., Coutinho, W., Appolinario, J.C., 2005. Treatment of obese adolescents with sibutramine: A randomized, double-blind, controlled study. J. Clin. Endocrinol. Metab. 90, 1460-1465. Gögen, 2011. Avrupa Birliği ve Türkiye’nin kalp sağlığı politikaları. Türk Kardiyol Dern. Arş. 39, 248-253.

Grief, S., Talamayan, K., 2008. Preventing Obesity in the Primary Care Setting. Prim. Care. 35, 625-643.

Hill, J.O., Wyatt, H., 2002. Outpatient management of obesity: A primary care perspective. Obes. Res.10, 124-130.

Hokino, S., Zateri, C., 2004. Obezite ve aerobik egzersizler. Türkiye Klinikleri J. PM&R. 4, 91-99.

Jakicic, J.M., Marcus, B.H., Gallagher, K.I., Napolitano, M., Lang, W., 2003. Effect of exercise duration and intensity on weight loss in overweight, sedentary women: A randomized trial. JAMA. 290, 1323-30.

Janssen, I., Katzmarzyk, P.T., Ross, R., 2002. Body mass index, waist circumference, and health risk: Evidence in support of current National Institutes of Health guidelines. Arch. Intern. Med. 162, 2074-2079.

Kang, J.K., Park, C.Y., 2012. Anti-Obesity Drugs: A Review about their effects and safety. Diabetes Metab. J. 36, 13-25.

Kelly, J., Tarnoff, M., Shikora, S., Thayer, B., Jones, D.B., Forse, R.A., Hutter, M.M., Fanelli, R., Lautz, D., Buckley, F., Munshi, I., Coe, N., 200Best practice recommendations for surgical care in weight loss surgery. Obes Res. 13, 227-233. Lau, D., Douketis, J.D., Morrison, K.M., Hramiak, I.M., Sharma, A.M., Ehud, Ur., 2007. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ. 176, 1-13.

Leung, W.Y., Thomas, G.N., Chan, J.C., Tomlinson, B., 2003. Weight management and current options in pharmacotherapy: Orlistat and sibutramine. Clin. Ther. 25, 58-80.

Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L.R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P.G., Morton, S.C., 200 Meta-analysis: Pharmacologic treatment of obesity. Ann. Intern. Med. 142, 532-546. Lobstein, T., Frelut, M.L., 2003. Prevalence of overweight among children in Europe. Obes. Rev. 4, 195-200.

Luján, J.A., Frutos, M.D., Hernández, Q., Liron, R., Cuenca, J.R., Valero, G., Parrilla, P., 2004. Laparoscopic versus open gastric bypass in the treatment of morbid obesity: A randomized prospective study. Ann. Surg. 239, 433-437.

Maahs, D., Gonzalez de Serna, D., Kolotkin, R., Ralston, S., Sandate, J., Qualls, C., Schade, D., 2006. Randomized, double-blind, placebocontrolled trial of orlistat for weight loss in adolescents. Endocr Pract.12, 18-28.

Mannucci, E., Dicembrini, I., Rotella, F., Rotella, C.M., 2008. Orlistat and sibutramine beyond weight loss. Nutr Metab. Cardiovasc. 18, 3423

McInnis, K.J., 2003. Diet., exercise, and the challenge of combating obesity in primary care. J. Cardiovasc. Nurs. 18, 93-100.